Piper Sandler Reaffirms “Overweight” Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “overweight” rating reissued by equities researchers at Piper Sandler in a report released on Friday,Benzinga reports. They presently have a $58.00 target price on the biotechnology company’s stock, up from their previous target price of $45.00. Piper Sandler’s price objective would indicate a potential upside of 90.16% from the company’s previous close.

CAPR has been the topic of a number of other reports. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday. Maxim Group lifted their price objective on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, December 4th. iA Financial set a $48.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a research report on Tuesday, March 10th. Finally, Oppenheimer lifted their price target on Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $46.09.

Capricor Therapeutics Trading Down 8.7%

Capricor Therapeutics stock opened at $30.50 on Friday. The firm has a market cap of $1.69 billion, a PE ratio of -13.50 and a beta of 0.37. Capricor Therapeutics has a 12 month low of $4.30 and a 12 month high of $40.37. The stock’s 50 day simple moving average is $25.70 and its two-hundred day simple moving average is $16.59.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, March 18th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). On average, equities research analysts forecast that Capricor Therapeutics will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC acquired a new position in Capricor Therapeutics during the fourth quarter worth $51,533,000. Tang Capital Management LLC purchased a new position in Capricor Therapeutics during the fourth quarter valued at $49,062,000. RA Capital Management L.P. acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $43,516,000. Darwin Global Management Ltd. acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $23,168,000. Finally, SB Capital Management Inc purchased a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $11,544,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

More Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA review resumed and a new PDUFA/decision date was set for Deramiocel — a major regulatory catalyst that can materially re‑rate the stock if approval looks likely. Capricor: Moving To ‘Buy’ Rating As New PDUFA Date Is Set For Deramiocel
• Positive Sentiment: Late‑breaking HOPE‑3 Phase 3 data presented at the MDA conference showed significant functional benefits for Deramiocel in DMD, supporting the therapy’s efficacy profile heading into the review. HOPE‑3 Data Release
• Positive Sentiment: Company financial positioning: Capricor highlights roughly $318M cash on hand and frames the FDA milestone as supporting potential commercialization, which reduces near‑term dilution risk. Cash & Commercialization Note
• Positive Sentiment: Analyst support has increased: B. Riley raised its price target to $63 (buy), Piper Sandler reaffirmed overweight and lifted its target to $58, and HC Wainwright reiterated buy — these upgrades boost conviction among buy‑side investors. Benzinga Coverage (B. Riley / Piper Sandler) HC Wainwright Reiterate
• Neutral Sentiment: Management tone is bullish on the regulatory path (CEO pushed back against the idea of only a conditional approval), which supports investor confidence but is not definitive on outcome. CEO Comment
• Negative Sentiment: Q4 results disappointed: EPS of ($0.62) missed consensus (~$0.51) and the loss widened year‑over‑year, prompting intraday selling and headlines calling out the miss. That weakens near‑term sentiment despite the regulatory upside. Q4 Earnings Miss Benzinga: Stock Slides

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.